Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 17, 2006

View Archived Issues

Novagali completes phase II study of ophthalmic formulation of ciclosporin

Chemicon and MorphoSys sign licensing agreement for research antibodies

Lantibio and TRB Chemedica sign agreement for Vismed

Canadian clearance for phase I study of SL-017 for acne and hair removal

Avid Radiopharmaceuticals closes first institutional financing round

Connetics to acquire PediaMed sales organization

SIRT1 activation: a new target for AD / News in Context

SB-509 set for phase II trial in diabetic neuropathy in H2 2006

New maintenance study of Peg-Intron in HCV patients coinfected with HIV

Hana Biosciences reports 2005 and 2006 milestones

Human Genome Sciences and Amgen sign license agreement

New peripherally selective DBH inhibitor from BIAL

Vitor shows therapeutic effect in cancer cachexia

Lucentis maintained or improved vision in approximately 95% of patients at one year

Benefits of memantine sustained for 1 year in Alzheimer's disease patients

Dosing, pharmacokinetics of BAY-43-9006 investigated in cancer patients

Interleukin-2 improves efficacy of WX-G250 in renal cell carcinoma

4F-Benzoyl-TE-14011 investigated in metastatic bladder cancer

BXL-628 can reduce prostate volume in benign prostatic hyperplasia

Fourth quarter update from Genzyme

New agents described for treating cardiovascular disorders

New possible treatments for gastrointestinal disorders described in recent patents

Recent GSK patent imparts novel agents for respiratory disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...